Multiple Myeloma Coverage from Every Angle

Twice-Weekly Ixazomib May Benefit Some Patients With Newly Diagnosed Multiple Myeloma

By: Sarah Campen, PharmD
Posted: Tuesday, August 21, 2018

According to a recent study published in the British Journal of Haematology, twice-weekly ixazomib plus lenalidomide and dexamethasone appears to improve long-term outcomes in patients with newly diagnosed multiple myeloma. However, twice-weekly dosing of the triplet therapy may be associated with greater toxicity than weekly dosing, found Paul G. Richardson, MD, of the Dana-Farber Cancer Institute, Boston, and colleagues.

“Further investigation of twice-weekly dosing is potentially warranted to define a subset of patients who are able to tolerate, and benefit from, more intensive therapy,” stated the investigators.

In phase I of the study, 14 patients were given ixazomib twice weekly at escalating doses. The recommended phase II dose was determined to be 3 mg, based on overall tolerability over multiple cycles. An additional 50 patients participated in phase II, receiving ixazomib at 3 mg twice weekly plus lenalidomide and dexamethasone for up to 48 weeks, followed by maintenance with twice-weekly ixazomib alone.

The overall response rate was 94%, with a median progression-free survival of 24.9 months. Very good partial responses and complete responses were observed in 68% and 24% of patients who responded to therapy, respectively. Responses were “rapid, deep, and durable, deepening over the course of treatment,” according to Dr. Richardson and colleagues.

As for toxicity, grade 3 treatment-related adverse events were reported in 64% of patients, including rash (13%), peripheral neuropathy (8%), and hyperglycemia (8%). Although adverse events appeared to be similar to those reported with once-weekly therapy in a separate study, more patients receiving twice-weekly treatment required dose reduction than did those receiving once-weekly treatment (66% vs. 20%).

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.